Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NextCure Inc. has secured global rights to the immunotherapy SIM0505 outside of Greater China, with a potential value of up to $745 million in upfront and milestone payments, supplemented by tiered royalties that could reach double-digit percentages on net sales. The company is experiencing positive developments in its drug candidates, particularly in the anti-tumor applications of its ADC programs, with preclinical data demonstrating strong anti-tumor activity and a favorable safety profile. Furthermore, the ongoing clinical trials, including a Phase I study for SIM0505 in the U.S., highlight NextCure's commitment to advancing its innovative cancer therapies, adding to the overall positive outlook for the company's financial prospects.

Bears say

NextCure Inc is experiencing a significant downward adjustment in its projected enterprise value, reducing it from $75 million to $37.5 million, which is indicative of overall weakening market sentiment. The reduction of the price target from $36 to $15 reflects concerns regarding the viability and clinical success of its therapeutic candidates, especially given the inherent risks associated with clinical trials in biopharmaceuticals. Additionally, with the speculative nature of its drug pipeline and the possibility of failure in clinical trials, there are heightened uncertainties regarding the realization of potential revenues in the near future.

Nextcure (NXTC) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Nextcure (NXTC) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.